Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development

Detalhes bibliográficos
Autor(a) principal: Marques, Rita
Data de Publicação: 2022
Outros Autores: Lacerda, Rafaela, Romão, Luísa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.18/8440
Resumo: This article belongs to the Special Issue mRNA Metabolism in Health and Disease 2.0.
id RCAP_95373c1d3d1bd6ed8e34ee7d8b3c2cfd
oai_identifier_str oai:repositorio.insa.pt:10400.18/8440
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy DevelopmentIRES Trans-acting FactorsIRES-based Multicistronic VectorsRNA-based TherapiesAntisense OligonucleotidesInternal Ribosome Entry SitesExpressão GénicaGenómica Funcional e EstruturalThis article belongs to the Special Issue mRNA Metabolism in Health and Disease 2.0.Many conditions can benefit from RNA-based therapies, namely, those targeting internal ribosome entry sites (IRESs) and their regulatory proteins, the IRES trans-acting factors (ITAFs). IRES-mediated translation is an alternative mechanism of translation initiation, known for maintaining protein synthesis when canonical translation is impaired. During a stress response, it contributes to cell reprogramming and adaptation to the new environment. The relationship between IRESs and ITAFs with tumorigenesis and resistance to therapy has been studied in recent years, proposing new therapeutic targets and treatments. In addition, IRES-dependent translation initiation dysregulation is also related to neurological and cardiovascular diseases, muscular atrophies, or other syndromes. The participation of these structures in the development of such pathologies has been studied, yet to a far lesser extent than in cancer. Strategies involving the disruption of IRES-ITAF interactions or the modification of ITAF expression levels may be used with great impact in the development of new therapeutics. In this review, we aim to comprehend the current data on groups of human pathologies associated with IRES and/or ITAF dysregulation and their application in the designing of new therapeutic approaches using them as targets or tools. Thus, we wish to summarise the evidence in the field hoping to open new promising lines of investigation toward personalised treatments.This work was partially supported by UID/MULTI/04046/2019 Research Unit grant (to BioISI)MDPIRepositório Científico do Instituto Nacional de SaúdeMarques, RitaLacerda, RafaelaRomão, Luísa2023-01-16T15:19:30Z2022-08-022022-08-02T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/8440engBiomedicines. 2022 Aug 2;10(8):1865. doi: 10.3390/biomedicines10081865. Review2227-905910.3390/biomedicines10081865info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-20T15:42:34Zoai:repositorio.insa.pt:10400.18/8440Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:43:04.699699Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
title Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
spellingShingle Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
Marques, Rita
IRES Trans-acting Factors
IRES-based Multicistronic Vectors
RNA-based Therapies
Antisense Oligonucleotides
Internal Ribosome Entry Sites
Expressão Génica
Genómica Funcional e Estrutural
title_short Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
title_full Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
title_fullStr Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
title_full_unstemmed Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
title_sort Internal Ribosome Entry Site (IRES)-Mediated Translation and Its Potential for Novel mRNA-Based Therapy Development
author Marques, Rita
author_facet Marques, Rita
Lacerda, Rafaela
Romão, Luísa
author_role author
author2 Lacerda, Rafaela
Romão, Luísa
author2_role author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Marques, Rita
Lacerda, Rafaela
Romão, Luísa
dc.subject.por.fl_str_mv IRES Trans-acting Factors
IRES-based Multicistronic Vectors
RNA-based Therapies
Antisense Oligonucleotides
Internal Ribosome Entry Sites
Expressão Génica
Genómica Funcional e Estrutural
topic IRES Trans-acting Factors
IRES-based Multicistronic Vectors
RNA-based Therapies
Antisense Oligonucleotides
Internal Ribosome Entry Sites
Expressão Génica
Genómica Funcional e Estrutural
description This article belongs to the Special Issue mRNA Metabolism in Health and Disease 2.0.
publishDate 2022
dc.date.none.fl_str_mv 2022-08-02
2022-08-02T00:00:00Z
2023-01-16T15:19:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/8440
url http://hdl.handle.net/10400.18/8440
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Biomedicines. 2022 Aug 2;10(8):1865. doi: 10.3390/biomedicines10081865. Review
2227-9059
10.3390/biomedicines10081865
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132176710631424

Registros relacionados